Introduction
Breast cancer (BC) remains the most frequent carcinoma in women, with an incidence of ~72,000 new cases per year occurring in Germany. Statistically, every 8th woman will contract breast cancer during her lifetime. In young women it is the most common cause of death. About every 10th woman diagnosed with BC in Germany is younger than 45 years [1] . Younger women are often affected by a more aggressive form of this disease [2, 3] . When treating this young population, special factors have to be taken into consideration: long recurrence-free survival (RS) and overall survival (OS) have to be weighed against quality of life and reintegration into family and work life. Therefore, young patients are potentially at risk for either undertreatment, as an assumed actual protection, or overtreatment while trying to achieve maximum benefit in the long term [4] .
Guidelines are based on the best available scientific evidence and clinical experience. They include systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances [5] . Because of different health care systems and thus different access to health care, national guidelines are needed. Wolters et al. [6] established that the recommended treatments within international guidelines are virtually identical, differing only marginally in adjuvant endocrine therapy. In Germany, the 'Arbeitsgemeinschaft Gynäkologische Onkologie' (AGO) releases annual recommendations reflecting upto-date research findings [7] . According to national consensuses, the AGO guidelines for treatment are, in fact, most frequently followed for BC therapy in Germany as they do incorporate the newest advances. Recently, international experts worked out a recommendation specifically referring to the management of young patients with breast cancer. This recommendation matches with those from the AGO but points out
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Summary Background: The purpose of the study was to characterize the treatment of young mothers with breast cancer in Germany and to investigate whether it followed applicable guidelines. Method: Retrospective data obtained between 2002 and 2011 for 1,053 mothers with children of < 12 years of age with adjuvantly treated loco-regional primary breast cancer were analyzed. Collected data included sociodemographic data, TNM stage, biology of tumor and therapies. Actually received therapies were compared to those suggested in guideline treatment plans. Results: The mean age of the patients was 39 years. 97% of the women with node positivity received an axillary dissection. Overall, 90% of the patients received chemotherapy with a guideline adherence range of 87-99% depending on clinical parameters. For radiation therapy, guideline adherence was high (range 82-100%). 95% of the patients with a hormone receptorpositive tumor received endocrine therapy; in 94%, tamoxifen therapy was performed in compliance with guidelines, whereas gonadotropin-releasing hormone (GnRH) agonist therapy complied with the guidelines in 52% of the cases. Conclusion: Guideline adherence in young mothers with breast cancer in Germany was high (with the exception of GnRH therapy), as comorbidity or the ambiguity of the therapeutic success does not need to be considered as much in this young, otherwise usually healthy, cohort compared to an age-heterogeneous group.
Pursche/Hedderich/Heinrichs/Baumann/ Banz-Jansen/Rody/Waldmann/Fischer Qualitative data are described using relative frequencies; quantitative data are described using means, standard deviations, and ranges. Data were analyzed using SPSS (IBM SPSS 19, SPSS Corporation). Table 2 describes the frequency of surgery and systemic therapies. With the exception of axillary surgery and gonadotropin-releasing hormone (GnRH) treatment, no relevant difference were seen between the cohorts I and II of young mothers. There was fewer sentinel lymph node biopsies (SLNBs) and SLNBs followed by axillary dissection (AD) in young mothers in group I than in II (24.5% and 16.8% vs. 47.5% and 24.7%) and more GnRH treatment (≤ 40 years 72.6% vs. 62.7% and > 40 years 36.6% vs. 11.4%). All together, the young mothers cohorts received more chemotherapy (88.9% vs. 83.4%), while OVIS patients seemed to receive more radiation therapy and breastconserving therapy (BCT). In the young mother cohorts, patients younger than 40 years were more likely to receive AD (46.7% vs. 34.5%), chemotherapy (93.3% vs. 82.6%) and a taxane (53.3% vs. 32.3%), even if they had an N0 status, compared to those older than 40 years. Figure 1 shows guideline conformity of various therapeutic parameters. All parameters show a high rate of guideline adherence in chemotherapy (range 87.0-99.0%) and radiation (range 80.2-100%). For endocrine therapy, we found a difference between tamoxifen therapy with a guideline conformity of 94.3% and GnRH analogues with a conformity of only 47.6%.
Results
The
Discussion
Only a relatively small number of patients are younger than 40 years at BC diagnosis. Although these patients are of essential and important aspects for young patients in more detail [8] . The BRENDA trial -a German retrospective multicenter cohort study including 9,156 patients with primary breast cancer recruited from 1992 to 2008 -examined the influence of therapy in adherence to guidelines (following the German S3 guideline) on RS and OS, and showed that guideline-consistent therapy improves RS and OS [9, 10] . To determine whether young patients in Germany were treated in accordance with applicable AGO guidelines, we evaluated the data of 1,053 women who participated in an in-patient rehabilitation mother-child program in Germany between 2007 and 2011 and, further, compared the treatment of young mothers with data of the OVIS (oncological treatment of tumor patients in Schleswig-Holstein) study, a mixed-age collective.
Material and Methods
Study Population and Data Collection
In this retrospective clinical cohort study we analyzed data from 1,053 patients from all over Germany with an adjuvantly treated loco-regional primary breast cancer who stayed in 'Klinik Ostseedeich' in Groemitz (Germany) for in-patient rehabilitation between February 2007 and September 2008 (young mothers I, 535 patients) or between October 2010 and November 2011 (young mothers II, 518 patients). Of the 1,053 patients, 58.4% were younger than 40 years, 24.1% were younger than 35 years. All patients had at least 1 child of < 12 years of age. Data included age of patient, number of children, date of diagnosis, place of residence, TNM-stage, tumor biology and treatment. The program was overseen by gynecologists from the Department of Gynecology and Obstetrics of the University of Schleswig-Holstein, Campus Lübeck. The study protocol was approved by the local ethics committee.
Comparison Population
The OVIS study evaluated the oncological health care of 1,927 patients who were diagnosed with primary breast cancer in Schleswig-Holstein between 2002 and 2004. As patients were recruited via the epidemiological cancer registry of Schleswig-Holstein, the study can be regarded as population based. A responder/non-responder comparison showed that participating women were representative for all breast cancer patients in Schleswig-Holstein [11, 12] . Physicians provided additional data on treatment for a subgroup of 1,141 patients. These women are comparable to the total OVIS cohort with regard to TNM, age at diagnosis, and treatment (as reported by patients) and were used in the present analysis.
Evaluating Guideline Adherence
To analyze guideline adherence, we designed treatment plans for each patient in accordance with the guidelines considering tumor stage and biology by following the AGO recommendations, and compared these plans to the actual therapy each patient had received.
Statistical Analysis
Our aim was to characterize the BC treatment of young mothers. We compared the results between cohorts I and II of young mothers, and further compared these with data from the OVIS study in a descriptive manner. In the literature, 'young BC patients' are defined as having a maximum age of 40 years at time breast cancer diagnosis. We therefore additionally divided the complete cohort of young mothers with respect to age (≤ 40 and > 40 years) and re-analyzed the results; OVIS patients were subclassified accordingly. (see table 2 ). Our results indicate the speed with which new recommendations can be implemented in BC therapy in Germany. Recently, the ACOSOG Z0011 trial showed for patients with BCT that AD in cN0 patients with positive SLNB has no effect on OS, RS or loco-regional risk of recurrence [17] after adequate radiation and systemic therapy. With regard to axillary staging, the AGO recommendations were revised in 2013 with AD no longer being mandatory in those cases [7] . To what extent this change will affect actual treatment practice remains to be seen. Radiation is recommended after BCT, 3 or more axillary lymph node metastases (≥ pN2) and T3/T4 tumors [7] . In the young mother cohorts we found high adherence to the guidelines (95.7-100%). Taking age into account as an independent risk factor, there was lower consistency with respect to radiation treatment: 83.2% in cohort I, 80.2% in cohort II and 86.7% in the OVIS group. It seems that this recommendation is not followed as often as the other recommendations.
Chemotherapy
A high percentage of patients in the cohorts I and II received chemotherapy (between 87.9 and 90.5%). A possible explanation could be that young age is regarded as an indespecial interest because of young age and their role in society, scientific literature on young BC patients is sparse.
In this study we analyzed a specific group of young patients, characterizing their BC treatment and evaluating the guideline conformity of their treatment. Young patients with BC have a worse prognosis [13, 14] than older women, and the risk for recurrence is also higher [15] . Therefore, the treating physician has to weigh the benefits of therapy against the potential harms, keeping in mind the goal of maximum long-term benefit with minimum long-term toxicity. Therapy in accordance with the guidelines improves RS and OS [2, 9, 10] , and should therefore be performed if possible. As presented at the Combating Breast Cancer Conference 2013, a continuous reduction of mortality in breast cancer has been observed over the past few years in Germany. Between 1998 and 2011, the patients of 35-40 years showed the highest reduction in mortality (39%) [13, 16] . This could be associated with the high adherence to the guidelines in the treatment for that young group.
Surgery and Radiation
After the publication of new findings, the AGO guidelines were changed to include SLNB in 2006 [7] . This resulted in a change in therapy strategies between the cohorts of the young mothers. In cohort I, AD was the standard method; for cohort therapy [25] . In the young mothers I group, of the patients < 40 years, 72.6%, and of those of ≥ 40 years 36.6%, received GnRH analogue treatment. In the young mother II group, 62.7% of those < 40 years, and 11.4% of those of ≥ 40 years received GnRH analogue treatment. Altogether the use of GnRH analogue is decreasing, primarily in patients older than 40 years. This is consistent with current guidelines in which the general use of GnRH analogues in premenopausal women is no longer recommended.
Herceptin
Expression of human epidermal growth factor receptor 2 (HER2) is an independent risk factor for reduced time to recurrence and OS if patients are untreated [26] . In 2006, the monoclonal antibody trastuzumab was approved for not-metastasized BC with overexpression of HER2/neu. 22.9% of the young mothers' groups had HER2/neu-positive BC, and 97.3% of those were treated with trastuzumab, which shows a high level of guideline conformity.
Conclusion
Our study indicates that young mothers with BC in Germany constitute a special group of patients with certain tumor characteristics. This retrospective analysis demonstrates a high level of adherence to the current guidelines.
Disclosure Statement
We declare that we have no conflict of interest. pendent risk factor for recurrence of BC [18] , and that clinicians consider more aggressive treatment for young BC patients as many studies have reported that young age at diagnosis is a predictor of poor survival [19] . This is consistent with our data in which patients younger than 35 years nearly always received chemotherapy (97.4% in the cohort of young mothers, 93.3% in the OVIS cohort). In node-positive cases, a taxane-based chemotherapy is strongly recommended [7] . In our study, 89.8% of the patients with node-positive BC received taxane, showing a high guideline adherence. Lymphangiosis or hemangiosis are also predictors for a poor outcome [20] , so that these patients should also be given chemotherapy [7] . All young mothers with hemangiosis and 98.3% of those with lymphangiosis received chemotherapy; again showing high guideline conformity.
A poorly differentiated tumor is generally more aggressive and at risk for occurrence of metastases [21] . In the cohorts of young mothers, 96.8% with G3 tumors were treated with chemotherapy compared to only 84.1% in the age-heterogeneous OVIS cohort. Previous studies identified advanced age as the main cause for deviations from guideline recommendations [22] . Reasons include the desire to avoid side effects in patients with co-morbidities, or refusal by patients to trade a reduced quality of life for increased life expectancy [23] . Young patients, besides the BC, are usually healthy. Therefore, they can in general be treated in accordance with guidelines. However, the guidelines do not take cardiac, nephrological or hepatic diseases into account, which may affect the decision for or against chemotherapy.
Endocrine Therapy
In hormone receptor-positive cases, tamoxifen is approved for premenopausal women to reduce recurrence rate and mortality in adjuvant therapy [24] . Of the hormone receptorpositive patients, 94.4% in the cohorts of young mothers received endocrine therapy (88.5% receiving tamoxifen) and 97.3% in the OVIS cohort, showing a high level of guideline conformity in both groups. In contrast, there is no conformity regarding treatment recommendations for GnRH analogue
